 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...4849505152535455565758...7475» |
- | Rayoqta (abicipar pegol) / Molecular Partners
Trial completion: SEQUOIA: Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jul 24, 2019
P3, N=946, Completed, Sponsor: Allergan
Active, not recruiting --> Completed
- | Rayoqta (abicipar pegol) / Molecular Partners
Trial completion: CDER: A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jul 24, 2019
P3, N=939, Completed, Sponsor: Allergan
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Observational data, Journal: Frequency and Risk Factors for Neovascular Glaucoma After Vitrectomy in Eyes with Diabetic Retinopathy: An Observational Study. (Pubmed Central) - Jul 20, 2019
Active, not recruiting --> Completed Preoperative high IOP combined with RVO, severe PDR, no postoperative intravitreal injection of ranibizumab (IVR), and higher HbA1c levels are significant predictors of NVG after vitrectomy.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Anti-VEGF therapy for age-related macular degeneration (Pubmed Central) - Jul 19, 2019
Preoperative high IOP combined with RVO, severe PDR, no postoperative intravitreal injection of ranibizumab (IVR), and higher HbA1c levels are significant predictors of NVG after vitrectomy. Aflibercept can be used as the first choice drug in the treatment of nAMD for it improves the anatomical parameters of the retina and the visual functions.
- | Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration. (Pubmed Central) - Jul 19, 2019
Good anatomical and stable functional responses are achievable with continued therapy. The lack of continued visual improvement may be representative of GA progression, reflecting the progression of late-stage nAMD in these patients.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Feasibility of support vector machine learning in age-related macular degeneration using small sample yielding sparse optical coherence tomography data. (Pubmed Central) - Jul 19, 2019
The SVML algorithm was as effective as the retina specialists were in detecting activity in wAMD. Support vector machine learning (SVML) may be a useful monitoring tool in wAMD suited for small samples that yield sparse OCT data possibly derived from self-measuring OCT-robots.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab. (Pubmed Central) - Jul 19, 2019
The ex vivo protein release was found to slower than the in vitro protein release for all samples. In conclusion, the DPPC-DPPG liposomes significantly improved the encapsulation and release profile of ranibizumab.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Safety of anti-VEGF treatments in a diabetic rat model and retinal cell culture. (Pubmed Central) - Jul 18, 2019
...Rats were also injected with the clinical dose of ranibizumab...Anti-VEGF treatment may be potentially detrimental to the retina by decreasing cellular metabolic activity and increasing cytotoxicity of retinal cells. The results provide a cautionary note to monitor both the retina and optic nerve status in patients undergoing frequent injections.
- | LKA651 / Novartis, MorphoSys
Enrollment open: Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Jul 17, 2019
P2, N=90, Recruiting, Sponsor: Novartis Pharmaceuticals
The results provide a cautionary note to monitor both the retina and optic nerve status in patients undergoing frequent injections. Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients. (Pubmed Central) - Jul 16, 2019
Clinically, anti-VEGF therapy appears to affect the optic nerve by increasing cup volume and increasing vertical cup/disk ratio over time. The results provide a cautionary note to monitor both the retina and optic nerve status in patients undergoing frequent injections.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Vicenda #avastin e #lucentis, @Roche e @NovartisItalia dovranno pagare la maxi multa dell'antitrust @GiuliaGrilloM5S @BeaLorenzin @farmindustrial @Altroconsumo @RegioneVeneto @zaiapresidente @sergioventuribo @Aifa_ufficiale @sbonaccini @forwardRPM https://t.co/XvRZ2ZluaQ (Twitter) - Jul 15, 2019
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: RainbowExt: Rainbow Extension Study (clinicaltrials.gov) - Jul 15, 2019
P3, N=180, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
The results provide a cautionary note to monitor both the retina and optic nerve status in patients undergoing frequent injections. Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New trial: SWITCH: Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema (clinicaltrials.gov) - Jul 14, 2019
P, N=40, Completed, Sponsor: Bernardete Pessoa MD
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy. (Pubmed Central) - Jul 13, 2019
Multiple logistic regression analysis revealed that absence of retreatment was associated with younger age (P = 2.2 × 10-4), female (P = 1.2 × 10-3), and the non-risk variants of ARMS2 A69S (P = 6.0 × 10-4). Although there were no significant differences in the retreatment rate between the two groups, PDT/IVA may be superior to PDT/IVR in terms of visual improvement at 24 months.
- | Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Journal: Prognostic factors of antiangiogenic therapy response in neovascular macular degeneration (Pubmed Central) - Jul 13, 2019
At least three 'loading' injections are required to determine drug responsiveness and acquire functional and morphological response data. Correlation of BCVA values at different timepoints (baseline/after 3 'loading' doses/after 12 month) was found.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Microvascular Retinal and Choroidal Changes in Retinal Vein Occlusion Analyzed by Two Different Optical Coherence Tomography Angiography Devices. (Pubmed Central) - Jul 13, 2019
A greater baseline SCT could be due to a choroidal exudation. OCTA imaged with PLEX® Elite allowed to differentiate ischemic and non-ischemic patients at baseline.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center. (Pubmed Central) - Jul 13, 2019
Same-day bilateral intravitreal anti-VEGF injections present a low rate of complications and are well tolerated by patients. This safe practice may reduce the burden on the health-care system and on the patients.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab. (Pubmed Central) - Jul 12, 2019
In this secondary analysis of randomized clinical trial data, patients with active nAMD in 1 eye appeared to have a high risk for fellow eye conversion. Such patients should be monitored closely.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Clinical preferences and trends of anti-vascular endothelial growth factor treatments for diabetic macular edema in Japan. (Pubmed Central) - Jul 11, 2019
The best-corrected visual acuity and the retinal thickness are important indicators to institute this therapy. The majority of the ophthalmologists use anti-VEGF treatment as first-line therapy and prefer the 1 + pro re nata regimen.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation. (Pubmed Central) - Jul 11, 2019
Despite this progress, successful translation to larger species, and ultimately humans, has yet to be demonstrated. Selection of animal models with relevant ocular anatomy and physiology, along with appropriate experimental design, is critical to enable more relevant feasibility assessments and increased probability of successful translation.
- | Lucentis (ranibizumab) / Roche, Novartis, Fovista (pegpleranib) / Roche, Astellas
Trial completion, Trial completion date, Trial primary completion date: A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (clinicaltrials.gov) - Jul 11, 2019
P1/2, N=3, Completed, Sponsor: National Eye Institute (NEI)
Selection of animal models with relevant ocular anatomy and physiology, along with appropriate experimental design, is critical to enable more relevant feasibility assessments and increased probability of successful translation. Active, not recruiting --> Completed | Trial completion date: May 2020 --> Jul 2019 | Trial primary completion date: May 2020 --> Jul 2019
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Switching to ranibizumab in diabetic macular oedema refractory to bevacizumab treatment. (Pubmed Central) - Jul 5, 2019
This effect is pronounced in patients with increased CST prior to the switch. Switching back to bevacizumab adds no further improvement.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Soluble Tei2 fusion protein inhibits retinopathy of prematurity occurrence via regulation of the Ang/Tie2 pathway. (Pubmed Central) - Jul 3, 2019
...Next, mice were randomly assigned into the PBS, soluble TEK receptor tyrosine kinase (sTie2)-fusion protein (Fc), angiopoietin 1 (Ang1), ranibizumab, ranibizumab + sTie2-Fc and ranibizumab + Ang1 treatment groups...In conclusion, the combined regulation of the Ang/Tie2 and the vascular endothelial growth factor (VEGF)/VEGF receptor pathways markedly increased the efficacy of treatment with retinal neovascularization (RNV). Regulation of these pathways has a potential for treating RNV, in particular ROP.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Reimbursement, Journal, Medicare: Estimating Medicare and patient savings from the use of bevacizumab for the treatment of exudative age-related macular degeneration. (Pubmed Central) - Jun 30, 2019
The cost savings from the use of bevacizumab from 2008-2015 for Medicare fee-for-service patients undergoing treatment for exudative AMD was estimated at $17.3 billion. Additional savings over the $17.3 billion would have accrued from the use of bevacizumab if diagnostic categories such as diabetic macular edema and retinal vein occlusion were included in this study.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice. (Pubmed Central) - Jun 30, 2019
Additional savings over the $17.3 billion would have accrued from the use of bevacizumab if diagnostic categories such as diabetic macular edema and retinal vein occlusion were included in this study. DME patients receiving anti-VEGF therapy in clinical practice undergo less frequent monitoring and intravitreal injections, and achieve inferior vision outcomes to patients in landmark clinical trials.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO. (Pubmed Central) - Jun 30, 2019
The SFCT in eyes with ME secondary to CRVO and BRVO was significantly thicker than that in fellow eyes, and decreased significantly within a short time in response to a single IVR injection. In further, the study showed that SFCT and SFCT change had no correlation with RVO subtypes.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal: Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial. (Pubmed Central) - Jun 28, 2019
P3
These findings do not support using changes in OCT CST as a surrogate for changes in VA in phase 3 clinical trials evaluating anti-VEGF for diabetic macular edema or as a guide to inform the physician or patient about changes in VA after anti-VEGF treatment. ClinicalTrials.gov identifier: NCT01627249.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment. (Pubmed Central) - Jun 28, 2019
The unsatisfactory results of this study elicited a change in the ROP treatment protocol in our medical centre. The study gives an insight into anatomical and functional outcomes of ROP treatment in the Central and Eastern European population.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Long-term effect of intravitreal ranibizumab therapy on retinal nerve fiber layer in eyes with exudative age-related macular degeneration. (Pubmed Central) - Jun 28, 2019
RNFL thickness decreased both equally in injected eyes and control eyes. Thus, no long-term effects of intravitreal ranibizumab were observed on the retinal nerve fiber layer thickness.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. (Pubmed Central) - Jun 28, 2019
Macular atrophy may occur more frequently in classic CNV. To maintain good vision, IVR treatment should be started earlier and performed continuously.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Retinal function determined by flicker ERGs before and soon after intravitreal injection of anti-VEGF agents. (Pubmed Central) - Jun 28, 2019
To maintain good vision, IVR treatment should be started earlier and performed continuously. The results indicate that an intravitreal anti-VEGF injection will increase the implicit times not only in the injected eye but also in the non-injected eye soon after the intravitreal injection.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic Activities. (Pubmed Central) - Jun 27, 2019
Our results therefore demonstrated the more potent and persistent suppressive activity of ranibizumab on the UM cells, possibly due to its higher level of uptake and prolonged intracellular retention. Further research on the endosome dynamics in UM cells might provide valuable insight into the response of these heterogenous tumors to therapeutic antibodies.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity. (Pubmed Central) - Jun 27, 2019
Serum VEGF levels in patients with ROP were suppressed for at least 7 days after IVR treatment. Although the clinical significance of this phenomenon is uncertain, its safety profile requires further investigation.
- | Lytenava (bevacizumab-vikg) / Outlook Therap
Enrollment open: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Jun 26, 2019
P3, N=220, Recruiting, Sponsor: Outlook Therapeutics, Inc.
Although the clinical significance of this phenomenon is uncertain, its safety profile requires further investigation. Not yet recruiting --> Recruiting
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: ALLERGIC REACTION UPON INTRAVITREAL ADMINISTRATION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS. (Pubmed Central) - Jun 26, 2019
Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin. These chemical origins may allow patients to receive pegaptanib or aflibercept despite having allergy to bevacizumab or ranibizumab.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, PK/PD data, Journal: Theoretical Insights Into the Retinal Dynamics of VEGF in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model. (Pubmed Central) - Jun 26, 2019
Lastly we have used the model to explore the impact of dose and binding parameters on the duration and depth of VEGF suppression in the aqueous and retinal compartments. Our simulations with the 3-compartment PKPD model provide new insight into the inter-patient variability in response to anti-VEGF therapy and offer a mechanistic framework for developing treatment regimens and molecules that may prolong the duration of retinal VEGF suppression.
- | Lucentis (ranibizumab) / Roche, Novartis, Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date: CASSIE: Combined Ranibizumab and Iluvien for Diabetic Macular Oedema (clinicaltrials.gov) - Jun 25, 2019
P2/3, N=0, Withdrawn, Sponsor: Imperial College London
Our simulations with the 3-compartment PKPD model provide new insight into the inter-patient variability in response to anti-VEGF therapy and offer a mechanistic framework for developing treatment regimens and molecules that may prolong the duration of retinal VEGF suppression. N=58 --> 0 | Trial completion date: Mar 2023 --> Sep 2023 | Initiation date: Mar 2019 --> Sep 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2022 --> Sep 2022
- | Ozurdex (dexamethasone intravitreal implant) / AbbVie, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Anti-VEGF Therapy Versus Dexamethasone Implant for DME (clinicaltrials.gov) - Jun 25, 2019
P4, N=150, Not yet recruiting, Sponsor: Sudhalkar Eye Hospital
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Polymeric, injectable, intravitreal hydrogel devices for posterior segment applications and interventions. (Pubmed Central) - Jun 22, 2019
This review will focus on the various biodegradable and non-biodegradable injectable intravitreal polymeric hydrogel devices, such as poly(ethylene glycol), poly(lactic-co-glycolic acid), silica, hyaluronic acid/dextran, silk, chitosan/alginate and poly(N-isopropylacrylamide)-based polymers, their compositions as well as the effects and results of these polymeric components on the device as a whole. Furthermore, it will briefly discuss therapeutic agents used in these devices, such as ranibizumab, dexamethasone, Avastin/bevacizumab and aflibercept, and a potential way forward by employing intelligent polymeric systems.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials. (Pubmed Central) - Jun 22, 2019
Compared with ranibizumab, corticosteroid implant did not have greater improved BCVA, but corticosteroid implant had less CST reduction. The advantages of corticosteroids are fewer injections, while the advantages of ranibizumab include fewer side effects.
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Reimbursement, Journal, Medicare: Analysis of Anti-Vascular Endothelial Growth Factor Injection Claims Data in US Medicare Part B Beneficiaries From 2012 to 2015. (Pubmed Central) - Jun 21, 2019
A total of 3.0% of ophthalmologists account for 17.6% to 31.0% of the total number of anti-VEGF injections administered nationally in the Medicare Part B population. Overall, bevacizumab and ranibizumab injections have decreased, coinciding with a 69.4% increase in aflibercept injections.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan. (Pubmed Central) - Jun 19, 2019
Increased utilization of anti-VEGF agents can reduce SVI and legal blindness in patients with DME in Japan. This would also be associated with substantial savings in patient and caregiver productivity loss.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Management of retinal artery macroaneurysm exudation in Wyburn-Mason syndrome with intravitreal ranibizumab. (Pubmed Central) - Jun 19, 2019
This would also be associated with substantial savings in patient and caregiver productivity loss. No abstract available
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-World Evidence: Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience. (Pubmed Central) - Jun 19, 2019
One-third of eyes with DME responded well to PRN treatment strategy from the first month without 3 loading doses of ranibizumab. Baseline visual acuity is the best predictor of vision at 1 and 2 years of follow-up.
- | Xlucane (ranibizumab biosimilar) / Stada, Xbrane, Helvetic
Enrollment open: XPLORE: Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis (clinicaltrials.gov) - Jun 16, 2019
P3, N=580, Recruiting, Sponsor: Xbrane Biopharma AB
Baseline visual acuity is the best predictor of vision at 1 and 2 years of follow-up. Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: In response to: Parodi MB, Iacono P, Zucchiatti et al. Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab. (Pubmed Central) - Jun 15, 2019
Although the authors wrote that CNV is secondary to MEWDS, another possible hypothesis is that CNV is secondary to PIC. Thus, MEWDS could be secondary to PIC and/or CNV.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal: Clinical observation on macular edema treated with treating different diseases with the same acupuncture comprehensive therapy (Pubmed Central) - Jun 15, 2019
Acupuncture comprehensive treatment can effectively treat macular edema, significantly improve the patient's vision, improve the subjective experience and the quality of life, and the shorter the course of the disease the more significant effect. Acupuncture comprehensive treatment is better than intramuscular injection of ranibizumab.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Central retinal venous occlusion in a child with hyperhomocysteinemia: A case report. (Pubmed Central) - Jun 14, 2019
Acupuncture comprehensive treatment is better than intramuscular injection of ranibizumab. All eye examinations should be performed in young patients, and they should undergo treatments immediately after is diagnosed as CRVO.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema. (Pubmed Central) - Jun 11, 2019
Although ranibizumab treatment in DMO over an 18-month period resulted in improvements in visual functioning and patient satisfaction, no correlation was found between the instruments used to measure these outcomes. Our finding of a lack of correlation between BCVA and the MacTSQ suggests the presence of psychophysical factors not measured by traditional means.
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Observational data, Journal: RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Data from an Observational Study. (Pubmed Central) - Jun 7, 2019
However, we found no significant difference in anatomical response or change in visual acuity between eyes treated with ranibizumab compared with aflibercept. Larger, prospectively designed, randomized studies with longer term follow-up may identify a difference between the two drugs that we did not detect.